Healthcare - Biotechnology - NASDAQ - US
$ 7.32
1.39 %
$ 1.17 B
Market Cap
-3.01
P/E
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.[ Read More ]
The intrinsic value of one NVAX stock under the base case scenario is HIDDEN Compared to the current market price of 7.32 USD, Novavax, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart NVAX
FINANCIALS
984 M
REVENUE
-567 M
OPERATING INCOME
-545 M
NET INCOME
-718 M
OPERATING CASH FLOW
-58.8 M
INVESTING CASH FLOW
4.47 M
FINANCING CASH FLOW
84.5 M
REVENUE
-134 M
OPERATING INCOME
-121 M
NET INCOME
-145 M
OPERATING CASH FLOW
31.9 M
INVESTING CASH FLOW
-97 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Novavax, Inc.
| Current Assets | 1.14 B |
| Cash & Short-Term Investments | 569 M |
| Receivables | 297 M |
| Other Current Assets | 278 M |
| Non-Current Assets | 711 M |
| Long-Term Investments | 4.88 M |
| PP&E | 491 M |
| Other Non-Current Assets | 216 M |
| Current Liabilities | 1.64 B |
| Accounts Payable | 133 M |
| Short-Term Debt | 5.14 M |
| Other Current Liabilities | 1.5 B |
| Non-Current Liabilities | 937 M |
| Long-Term Debt | 224 M |
| Other Non-Current Liabilities | 713 M |
EFFICIENCY
Earnings Waterfall
Novavax, Inc.
| Revenue | 984 M |
| Cost Of Revenue | 344 M |
| Gross Profit | 640 M |
| Operating Expenses | 779 M |
| Operating Income | -567 M |
| Other Expenses | -21.4 M |
| Net Income | -545 M |
RATIOS
65.05%
GROSS MARGIN
-57.59%
OPERATING MARGIN
-55.41%
NET MARGIN
76.03%
ROE
-30.32%
ROA
103.59%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Novavax, Inc.
| Net Income | -545 M |
| Depreciation & Amortization | 41.2 M |
| Capital Expenditures | -58.8 M |
| Stock-Based Compensation | 85.4 M |
| Change in Working Capital | -377 M |
| Others | 432 M |
| Free Cash Flow | -773 M |
Wall Street Analysts Price Targets
Novavax, Inc.
Wall Street analysts predict an average 1-year price target for NVAX of $22.2 , with forecasts ranging from a low of $14 to a high of $31 .
NVAX Lowest Price Target
Wall Street Target
14 USD
91.26%
NVAX Average Price Target
Wall Street Target
22.2 USD
203.96%
NVAX Highest Price Target
Wall Street Target
31 USD
323.50%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Novavax, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
410 K USD 2
6-9 MONTHS
658 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
4 months ago
Jun 21, 2024
|
Sell 106 K USD
|
YOUNG JAMES F
Director |
- 7500
|
14.09 USD |
|
5 months ago
Jun 18, 2024
|
Sell 87.1 K USD
|
YOUNG JAMES F
Director |
- 6393
|
13.62 USD |
|
5 months ago
Jun 18, 2024
|
Sell 15.8 K USD
|
YOUNG JAMES F
Director |
- 1107
|
14.28 USD |
|
5 months ago
Jun 17, 2024
|
Sell 181 K USD
|
Dubovsky Filip
President, R&D |
- 12500
|
14.46 USD |
|
5 months ago
Jun 17, 2024
|
Sell 20.4 K USD
|
Dubovsky Filip
President, R&D |
- 1404
|
14.54 USD |
|
6 months ago
May 14, 2024
|
Sell 658 K USD
|
Dubovsky Filip
President, R&D |
- 47312
|
13.9 USD |
|
1 year ago
Mar 10, 2023
|
Bought 6.5 K USD
|
Glenn Gregory M
President, R&D |
+ 1000
|
6.5 USD |
|
1 year ago
Mar 07, 2023
|
Bought 14.1 K USD
|
Glenn Gregory M
President, R&D |
+ 2000
|
7.044 USD |
|
1 year ago
Mar 06, 2023
|
Bought 22.5 K USD
|
Glenn Gregory M
President, R&D |
+ 3000
|
7.4845 USD |
|
2 years ago
Mar 31, 2022
|
Sell 656 K USD
|
YOUNG JAMES F
Director |
- 8945
|
73.2867 USD |
|
2 years ago
Mar 31, 2022
|
Sell 242 K USD
|
YOUNG JAMES F
Director |
- 3255
|
74.2501 USD |
|
2 years ago
Mar 31, 2022
|
Sell 22.5 K USD
|
YOUNG JAMES F
director: |
- 300
|
75.1033 USD |
|
2 years ago
Jan 03, 2022
|
Sell 54.7 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
136.82 USD |
|
2 years ago
Jan 03, 2022
|
Sell 55.1 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
137.85 USD |
|
2 years ago
Jan 03, 2022
|
Sell 139 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 997
|
139.0768 USD |
|
2 years ago
Jan 03, 2022
|
Sell 70 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 500
|
140.052 USD |
|
2 years ago
Jan 03, 2022
|
Sell 113 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 800
|
141.6875 USD |
|
2 years ago
Jan 03, 2022
|
Sell 114 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 800
|
142.6463 USD |
|
2 years ago
Jan 03, 2022
|
Sell 144 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 1003
|
143.639 USD |
|
2 years ago
Jan 03, 2022
|
Sell 14.4 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 100
|
144.43 USD |
|
2 years ago
Dec 31, 2021
|
Sell 541 K USD
|
YOUNG JAMES F
Director |
- 3750
|
144.1602 USD |
|
2 years ago
Dec 20, 2021
|
Sell 1.15 M USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 5000
|
230 USD |
|
2 years ago
Dec 15, 2021
|
Sell 19.8 K USD
|
Glenn Gregory M
President, R&D |
- 117
|
168.8217 USD |
|
2 years ago
Dec 15, 2021
|
Sell 36.3 K USD
|
Glenn Gregory M
President, R&D |
- 213
|
170.4647 USD |
|
2 years ago
Dec 15, 2021
|
Sell 43.6 K USD
|
Glenn Gregory M
President, R&D |
- 254
|
171.4693 USD |
|
2 years ago
Dec 15, 2021
|
Sell 42.7 K USD
|
Glenn Gregory M
President, R&D |
- 248
|
172.3771 USD |
|
2 years ago
Dec 15, 2021
|
Sell 15.8 K USD
|
Glenn Gregory M
President, R&D |
- 91
|
173.2926 USD |
|
2 years ago
Dec 15, 2021
|
Sell 23.9 K USD
|
Glenn Gregory M
President, R&D |
- 137
|
174.6519 USD |
|
2 years ago
Dec 15, 2021
|
Sell 11.8 K USD
|
Glenn Gregory M
President, R&D |
- 67
|
175.8931 USD |
|
2 years ago
Dec 15, 2021
|
Sell 39.4 K USD
|
Glenn Gregory M
President, R&D |
- 223
|
176.8253 USD |
|
2 years ago
Dec 15, 2021
|
Sell 18.4 K USD
|
Glenn Gregory M
President, R&D |
- 103
|
178.9927 USD |
|
2 years ago
Dec 15, 2021
|
Sell 37 K USD
|
Glenn Gregory M
President, R&D |
- 206
|
179.5781 USD |
|
2 years ago
Dec 15, 2021
|
Sell 4.88 K USD
|
Glenn Gregory M
President, R&D |
- 27
|
180.6211 USD |
|
2 years ago
Dec 07, 2021
|
Sell 30.1 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
150.295 USD |
|
2 years ago
Dec 07, 2021
|
Sell 15.2 K USD
|
Glenn Gregory M
President, R&D |
- 100
|
151.85 USD |
|
2 years ago
Dec 07, 2021
|
Sell 61 K USD
|
Glenn Gregory M
President, R&D |
- 397
|
153.5286 USD |
|
2 years ago
Dec 07, 2021
|
Sell 15.4 K USD
|
Glenn Gregory M
President, R&D |
- 100
|
154.38 USD |
|
2 years ago
Dec 07, 2021
|
Sell 46.9 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
156.2433 USD |
|
2 years ago
Dec 07, 2021
|
Sell 31.4 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
157.02 USD |
|
2 years ago
Dec 07, 2021
|
Sell 47.5 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
158.4233 USD |
|
2 years ago
Dec 07, 2021
|
Sell 48.2 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
160.5233 USD |
|
2 years ago
Dec 07, 2021
|
Sell 48.5 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
161.6333 USD |
|
2 years ago
Dec 07, 2021
|
Sell 32.6 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
162.825 USD |
|
2 years ago
Dec 07, 2021
|
Sell 49.4 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
164.7667 USD |
|
2 years ago
Dec 07, 2021
|
Sell 49.7 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
165.7967 USD |
|
2 years ago
Dec 07, 2021
|
Sell 50.1 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
167.06 USD |
|
2 years ago
Dec 07, 2021
|
Sell 67.5 K USD
|
Glenn Gregory M
President, R&D |
- 400
|
168.77 USD |
|
2 years ago
Dec 07, 2021
|
Sell 34.3 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
171.3 USD |
|
2 years ago
Dec 07, 2021
|
Sell 34.6 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
173.135 USD |
|
2 years ago
Dec 07, 2021
|
Sell 158 K USD
|
Glenn Gregory M
President, R&D |
- 900
|
175.1322 USD |
|
2 years ago
Dec 07, 2021
|
Sell 141 K USD
|
Glenn Gregory M
President, R&D |
- 800
|
176.195 USD |
|
2 years ago
Dec 07, 2021
|
Sell 89.1 K USD
|
Glenn Gregory M
President, R&D |
- 500
|
178.208 USD |
|
2 years ago
Dec 07, 2021
|
Sell 89.7 K USD
|
Glenn Gregory M
President, R&D |
- 500
|
179.36 USD |
|
2 years ago
Dec 07, 2021
|
Sell 90.1 K USD
|
Glenn Gregory M
President, R&D |
- 500
|
180.294 USD |
|
2 years ago
Dec 07, 2021
|
Sell 155 K USD
|
Glenn Gregory M
President, R&D |
- 853
|
182.2955 USD |
|
2 years ago
Dec 07, 2021
|
Sell 18.3 K USD
|
Glenn Gregory M
President, R&D |
- 100
|
182.96 USD |
|
2 years ago
Dec 01, 2021
|
Sell 133 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 691
|
192.6378 USD |
|
2 years ago
Dec 01, 2021
|
Sell 155 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 800
|
193.7925 USD |
|
2 years ago
Dec 01, 2021
|
Sell 175 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 900
|
194.5389 USD |
|
2 years ago
Dec 01, 2021
|
Sell 185 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 943
|
196.1101 USD |
|
2 years ago
Dec 01, 2021
|
Sell 59.2 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 300
|
197.1867 USD |
|
2 years ago
Dec 01, 2021
|
Sell 79.3 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
198.35 USD |
|
2 years ago
Dec 01, 2021
|
Sell 59.9 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 300
|
199.8133 USD |
|
2 years ago
Dec 01, 2021
|
Sell 60.3 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 300
|
200.92 USD |
|
2 years ago
Dec 01, 2021
|
Sell 74.1 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 366
|
202.3617 USD |
|
2 years ago
Nov 30, 2021
|
Sell 23 K USD
|
Glenn Gregory M
President, R&D |
- 121
|
189.9787 USD |
|
2 years ago
Nov 30, 2021
|
Sell 765 USD
|
Glenn Gregory M
President, R&D |
- 4
|
191.29 USD |
|
2 years ago
Nov 30, 2021
|
Sell 42.8 K USD
|
Glenn Gregory M
President, R&D |
- 222
|
192.5762 USD |
|
2 years ago
Nov 30, 2021
|
Sell 38.9 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
194.615 USD |
|
2 years ago
Nov 30, 2021
|
Sell 101 K USD
|
Glenn Gregory M
President, R&D |
- 518
|
195.8687 USD |
|
2 years ago
Nov 30, 2021
|
Sell 70.2 K USD
|
Glenn Gregory M
President, R&D |
- 356
|
197.3079 USD |
|
2 years ago
Nov 30, 2021
|
Sell 166 K USD
|
Glenn Gregory M
President, R&D |
- 836
|
198.1697 USD |
|
2 years ago
Nov 30, 2021
|
Sell 135 K USD
|
Glenn Gregory M
President, R&D |
- 678
|
199.2499 USD |
|
2 years ago
Nov 30, 2021
|
Sell 144 K USD
|
Glenn Gregory M
President, R&D |
- 717
|
200.4041 USD |
|
2 years ago
Nov 30, 2021
|
Sell 68 K USD
|
Glenn Gregory M
President, R&D |
- 338
|
201.2272 USD |
|
2 years ago
Nov 30, 2021
|
Sell 145 K USD
|
Glenn Gregory M
President, R&D |
- 715
|
202.366 USD |
|
2 years ago
Nov 30, 2021
|
Sell 94.8 K USD
|
Glenn Gregory M
President, R&D |
- 465
|
203.7942 USD |
|
2 years ago
Nov 30, 2021
|
Sell 90.5 K USD
|
Glenn Gregory M
President, R&D |
- 439
|
206.0645 USD |
|
2 years ago
Nov 30, 2021
|
Sell 73.1 K USD
|
Glenn Gregory M
President, R&D |
- 353
|
207.1935 USD |
|
2 years ago
Nov 30, 2021
|
Sell 303 K USD
|
Glenn Gregory M
President, R&D |
- 1450
|
208.7772 USD |
|
2 years ago
Nov 30, 2021
|
Sell 184 K USD
|
Glenn Gregory M
President, R&D |
- 879
|
209.8055 USD |
|
2 years ago
Nov 30, 2021
|
Sell 116 K USD
|
Glenn Gregory M
President, R&D |
- 551
|
210.5742 USD |
|
2 years ago
Nov 30, 2021
|
Sell 21.2 K USD
|
Glenn Gregory M
President, R&D |
- 100
|
211.75 USD |
|
2 years ago
Nov 29, 2021
|
Sell 1.14 M USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 5000
|
228.72 USD |
|
2 years ago
Nov 26, 2021
|
Sell 39.8 K USD
|
Glenn Gregory M
President, R&D |
- 185
|
215.0036 USD |
|
2 years ago
Nov 26, 2021
|
Sell 56.2 K USD
|
Glenn Gregory M
President, R&D |
- 260
|
216.1873 USD |
|
2 years ago
Nov 26, 2021
|
Sell 71.9 K USD
|
Glenn Gregory M
President, R&D |
- 331
|
217.3602 USD |
|
2 years ago
Nov 26, 2021
|
Sell 137 K USD
|
Glenn Gregory M
President, R&D |
- 626
|
218.2544 USD |
|
2 years ago
Nov 26, 2021
|
Sell 90.3 K USD
|
Glenn Gregory M
President, R&D |
- 412
|
219.2546 USD |
|
2 years ago
Nov 26, 2021
|
Sell 34.1 K USD
|
Glenn Gregory M
President, R&D |
- 155
|
220.2217 USD |
|
2 years ago
Nov 26, 2021
|
Sell 25.2 K USD
|
Glenn Gregory M
President, R&D |
- 114
|
221.2429 USD |
|
2 years ago
Nov 23, 2021
|
Sell 157 K USD
|
Glenn Gregory M
President, R&D |
- 800
|
196.4288 USD |
|
2 years ago
Nov 23, 2021
|
Sell 276 K USD
|
Glenn Gregory M
President, R&D |
- 1400
|
197.4421 USD |
|
2 years ago
Nov 23, 2021
|
Sell 252 K USD
|
Glenn Gregory M
President, R&D |
- 1271
|
198.4676 USD |
|
2 years ago
Nov 23, 2021
|
Sell 277 K USD
|
Glenn Gregory M
President, R&D |
- 1387
|
199.5096 USD |
|
2 years ago
Nov 23, 2021
|
Sell 321 K USD
|
Glenn Gregory M
President, R&D |
- 1600
|
200.5544 USD |
|
2 years ago
Nov 23, 2021
|
Sell 145 K USD
|
Glenn Gregory M
President, R&D |
- 722
|
201.4786 USD |
|
2 years ago
Nov 23, 2021
|
Sell 176 K USD
|
Glenn Gregory M
President, R&D |
- 870
|
202.646 USD |
|
2 years ago
Nov 23, 2021
|
Sell 40.7 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
203.615 USD |
|
3 years ago
Nov 16, 2021
|
Sell 83.4 K USD
|
Glenn Gregory M
President, R&D |
- 500
|
166.892 USD |
|
3 years ago
Nov 16, 2021
|
Sell 247 K USD
|
Glenn Gregory M
President, R&D |
- 1472
|
167.9519 USD |
|
3 years ago
Nov 16, 2021
|
Sell 224 K USD
|
Glenn Gregory M
President, R&D |
- 1326
|
168.906 USD |
|
3 years ago
Nov 16, 2021
|
Sell 741 K USD
|
Glenn Gregory M
President, R&D |
- 4352
|
170.2613 USD |
|
3 years ago
Nov 16, 2021
|
Sell 103 K USD
|
Glenn Gregory M
President, R&D |
- 600
|
170.9367 USD |
|
3 years ago
Nov 15, 2021
|
Sell 203 K USD
|
Glenn Gregory M
President, R&D |
- 1183
|
172.0167 USD |
|
3 years ago
Nov 09, 2021
|
Sell 65.7 K USD
|
Glenn Gregory M
President, R&D |
- 400
|
164.2325 USD |
|
3 years ago
Nov 09, 2021
|
Sell 232 K USD
|
Glenn Gregory M
President, R&D |
- 1400
|
165.7236 USD |
|
3 years ago
Nov 09, 2021
|
Sell 300 K USD
|
Glenn Gregory M
President, R&D |
- 1800
|
166.5461 USD |
|
3 years ago
Nov 09, 2021
|
Sell 336 K USD
|
Glenn Gregory M
President, R&D |
- 2000
|
167.7585 USD |
|
3 years ago
Nov 09, 2021
|
Sell 113 K USD
|
Glenn Gregory M
President, R&D |
- 672
|
168.4589 USD |
|
3 years ago
Nov 09, 2021
|
Sell 251 K USD
|
Glenn Gregory M
President, R&D |
- 1478
|
169.5416 USD |
|
3 years ago
Nov 09, 2021
|
Sell 68.2 K USD
|
Glenn Gregory M
President, R&D |
- 400
|
170.5475 USD |
|
3 years ago
Nov 09, 2021
|
Sell 17.1 K USD
|
Glenn Gregory M
President, R&D |
- 100
|
171.48 USD |
|
3 years ago
Nov 03, 2021
|
Sell 1 M USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 5000
|
200 USD |
|
3 years ago
Nov 02, 2021
|
Sell 106 K USD
|
Glenn Gregory M
President, R&D |
- 600
|
177.115 USD |
|
3 years ago
Nov 02, 2021
|
Sell 214 K USD
|
Glenn Gregory M
President, R&D |
- 1200
|
178.1242 USD |
|
3 years ago
Nov 02, 2021
|
Sell 161 K USD
|
Glenn Gregory M
President, R&D |
- 900
|
179.0889 USD |
|
3 years ago
Nov 02, 2021
|
Sell 108 K USD
|
Glenn Gregory M
President, R&D |
- 600
|
180.4133 USD |
|
3 years ago
Nov 02, 2021
|
Sell 122 K USD
|
Glenn Gregory M
President, R&D |
- 670
|
181.5482 USD |
|
3 years ago
Nov 02, 2021
|
Sell 110 K USD
|
Glenn Gregory M
President, R&D |
- 600
|
182.5783 USD |
|
3 years ago
Nov 02, 2021
|
Sell 147 K USD
|
Glenn Gregory M
President, R&D |
- 800
|
183.575 USD |
|
3 years ago
Nov 02, 2021
|
Sell 55.8 K USD
|
Glenn Gregory M
President, R&D |
- 302
|
184.8187 USD |
|
3 years ago
Nov 02, 2021
|
Sell 93 K USD
|
Glenn Gregory M
President, R&D |
- 500
|
186.094 USD |
|
3 years ago
Nov 02, 2021
|
Sell 56.2 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
187.2567 USD |
|
3 years ago
Nov 02, 2021
|
Sell 56.5 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
188.33 USD |
|
3 years ago
Nov 02, 2021
|
Sell 19 K USD
|
Glenn Gregory M
President, R&D |
- 100
|
190.29 USD |
|
3 years ago
Nov 02, 2021
|
Sell 77.3 K USD
|
Glenn Gregory M
President, R&D |
- 400
|
193.155 USD |
|
3 years ago
Nov 02, 2021
|
Sell 58.3 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
194.4 USD |
|
3 years ago
Nov 02, 2021
|
Sell 73.9 K USD
|
Glenn Gregory M
President, R&D |
- 378
|
195.5376 USD |
|
3 years ago
Nov 02, 2021
|
Sell 39.2 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
196.24 USD |
|
3 years ago
Nov 02, 2021
|
Sell 19.8 K USD
|
Glenn Gregory M
President, R&D |
- 100
|
197.51 USD |
|
3 years ago
Nov 01, 2021
|
Sell 62.1 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
155.1625 USD |
|
3 years ago
Nov 01, 2021
|
Sell 46.8 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 300
|
155.96 USD |
|
3 years ago
Nov 01, 2021
|
Sell 126 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 800
|
157.42 USD |
|
3 years ago
Nov 01, 2021
|
Sell 63.4 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
158.535 USD |
|
3 years ago
Nov 01, 2021
|
Sell 54.8 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 343
|
159.904 USD |
|
3 years ago
Nov 01, 2021
|
Sell 64.8 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
162.1 USD |
|
3 years ago
Nov 01, 2021
|
Sell 16.3 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 100
|
162.69 USD |
|
3 years ago
Nov 01, 2021
|
Sell 49.2 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 300
|
164.0167 USD |
|
3 years ago
Nov 01, 2021
|
Sell 33.1 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 200
|
165.665 USD |
|
3 years ago
Nov 01, 2021
|
Sell 33.4 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 200
|
167.145 USD |
|
3 years ago
Nov 01, 2021
|
Sell 67.3 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
168.32 USD |
|
3 years ago
Nov 01, 2021
|
Sell 33.8 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 200
|
169.045 USD |
|
3 years ago
Nov 01, 2021
|
Sell 85.4 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 500
|
170.882 USD |
|
3 years ago
Nov 01, 2021
|
Sell 51.7 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 300
|
172.4433 USD |
|
3 years ago
Nov 01, 2021
|
Sell 27.2 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 157
|
173.15 USD |
|
3 years ago
Oct 29, 2021
|
Sell 5.67 K USD
|
Glenn Gregory M
President, R&D |
- 39
|
145.4077 USD |
|
3 years ago
Oct 29, 2021
|
Sell 15.8 K USD
|
Glenn Gregory M
President, R&D |
- 108
|
146.5061 USD |
|
3 years ago
Oct 29, 2021
|
Sell 20.4 K USD
|
Glenn Gregory M
President, R&D |
- 138
|
148.0814 USD |
|
3 years ago
Oct 29, 2021
|
Sell 52.6 K USD
|
Glenn Gregory M
President, R&D |
- 353
|
148.9851 USD |
|
3 years ago
Oct 29, 2021
|
Sell 2.39 K USD
|
Glenn Gregory M
President, R&D |
- 16
|
149.64 USD |
|
3 years ago
Oct 29, 2021
|
Sell 3.96 K USD
|
Glenn Gregory M
President, R&D |
- 26
|
152.1646 USD |
|
3 years ago
Oct 26, 2021
|
Sell 196 K USD
|
Glenn Gregory M
President, R&D |
- 1500
|
130.9347 USD |
|
3 years ago
Oct 26, 2021
|
Sell 396 K USD
|
Glenn Gregory M
President, R&D |
- 3000
|
131.91 USD |
|
3 years ago
Oct 26, 2021
|
Sell 417 K USD
|
Glenn Gregory M
President, R&D |
- 3134
|
133.0173 USD |
|
3 years ago
Oct 26, 2021
|
Sell 227 K USD
|
Glenn Gregory M
President, R&D |
- 1700
|
133.8229 USD |
|
3 years ago
Oct 26, 2021
|
Sell 135 K USD
|
Glenn Gregory M
President, R&D |
- 1000
|
135.16 USD |
|
3 years ago
Oct 19, 2021
|
Sell 256 K USD
|
Glenn Gregory M
President, R&D |
- 1591
|
161.0007 USD |
|
3 years ago
Oct 19, 2021
|
Sell 145 K USD
|
Glenn Gregory M
President, R&D |
- 893
|
162.0489 USD |
|
3 years ago
Oct 19, 2021
|
Sell 65.2 K USD
|
Glenn Gregory M
President, R&D |
- 400
|
163.0075 USD |
|
3 years ago
Oct 19, 2021
|
Sell 231 K USD
|
Glenn Gregory M
President, R&D |
- 1400
|
164.8475 USD |
|
3 years ago
Oct 19, 2021
|
Sell 166 K USD
|
Glenn Gregory M
President, R&D |
- 1000
|
165.984 USD |
|
3 years ago
Oct 19, 2021
|
Sell 228 K USD
|
Glenn Gregory M
President, R&D |
- 1366
|
167.0825 USD |
|
3 years ago
Oct 19, 2021
|
Sell 135 K USD
|
Glenn Gregory M
President, R&D |
- 800
|
168.4929 USD |
|
3 years ago
Oct 19, 2021
|
Sell 51 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
169.8467 USD |
|
3 years ago
Oct 19, 2021
|
Sell 68.4 K USD
|
Glenn Gregory M
President, R&D |
- 400
|
171.015 USD |
|
3 years ago
Oct 19, 2021
|
Sell 17.2 K USD
|
Glenn Gregory M
President, R&D |
- 100
|
172.03 USD |
|
3 years ago
Oct 15, 2021
|
Sell 201 K USD
|
Glenn Gregory M
President, R&D |
- 1183
|
170 USD |
|
3 years ago
Oct 12, 2021
|
Sell 162 K USD
|
Glenn Gregory M
President, R&D |
- 1000
|
161.582 USD |
|
3 years ago
Oct 12, 2021
|
Sell 471 K USD
|
Glenn Gregory M
President, R&D |
- 2900
|
162.4493 USD |
|
3 years ago
Oct 12, 2021
|
Sell 467 K USD
|
Glenn Gregory M
President, R&D |
- 2858
|
163.3817 USD |
|
3 years ago
Oct 12, 2021
|
Sell 132 K USD
|
Glenn Gregory M
President, R&D |
- 800
|
164.5013 USD |
|
3 years ago
Oct 12, 2021
|
Sell 65 K USD
|
Glenn Gregory M
President, R&D |
- 392
|
165.6991 USD |
|
3 years ago
Oct 12, 2021
|
Sell 50 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
166.7767 USD |
|
3 years ago
Oct 05, 2021
|
Sell 251 K USD
|
Glenn Gregory M
President, R&D |
- 1471
|
170.7953 USD |
|
3 years ago
Oct 05, 2021
|
Sell 378 K USD
|
Glenn Gregory M
President, R&D |
- 2200
|
171.8582 USD |
|
3 years ago
Oct 05, 2021
|
Sell 121 K USD
|
Glenn Gregory M
President, R&D |
- 700
|
172.7014 USD |
|
3 years ago
Oct 05, 2021
|
Sell 122 K USD
|
Glenn Gregory M
President, R&D |
- 700
|
174.1243 USD |
|
3 years ago
Oct 05, 2021
|
Sell 105 K USD
|
Glenn Gregory M
President, R&D |
- 600
|
175.3233 USD |
|
3 years ago
Oct 05, 2021
|
Sell 88.2 K USD
|
Glenn Gregory M
President, R&D |
- 500
|
176.488 USD |
|
3 years ago
Oct 05, 2021
|
Sell 53.2 K USD
|
Glenn Gregory M
President, R&D |
- 300
|
177.3133 USD |
|
3 years ago
Oct 05, 2021
|
Sell 107 K USD
|
Glenn Gregory M
President, R&D |
- 600
|
178.3733 USD |
|
3 years ago
Oct 05, 2021
|
Sell 71.8 K USD
|
Glenn Gregory M
President, R&D |
- 400
|
179.3875 USD |
|
3 years ago
Oct 05, 2021
|
Sell 72.2 K USD
|
Glenn Gregory M
President, R&D |
- 400
|
180.41 USD |
|
3 years ago
Oct 05, 2021
|
Sell 32.6 K USD
|
Glenn Gregory M
President, R&D |
- 179
|
182.0475 USD |
|
3 years ago
Oct 05, 2021
|
Sell 36.6 K USD
|
Glenn Gregory M
President, R&D |
- 200
|
183.14 USD |
|
3 years ago
Oct 04, 2021
|
Sell 232 K USD
|
Erck Stanley C
President and CEO |
- 1392
|
166.9835 USD |
|
3 years ago
Oct 04, 2021
|
Sell 646 K USD
|
Erck Stanley C
President and CEO |
- 3746
|
172.3631 USD |
|
3 years ago
Oct 04, 2021
|
Sell 874 K USD
|
Erck Stanley C
President and CEO |
- 5038
|
173.4476 USD |
|
3 years ago
Oct 04, 2021
|
Sell 541 K USD
|
Erck Stanley C
President and CEO |
- 3100
|
174.5619 USD |
|
3 years ago
Oct 04, 2021
|
Sell 632 K USD
|
Erck Stanley C
President and CEO |
- 3600
|
175.6106 USD |
|
3 years ago
Oct 04, 2021
|
Sell 829 K USD
|
Erck Stanley C
President and CEO |
- 4700
|
176.4753 USD |
|
3 years ago
Oct 04, 2021
|
Sell 1.58 M USD
|
Erck Stanley C
President and CEO |
- 8890
|
177.5843 USD |
|
3 years ago
Oct 04, 2021
|
Sell 1.53 M USD
|
Erck Stanley C
President and CEO |
- 8563
|
178.4634 USD |
|
3 years ago
Oct 04, 2021
|
Sell 592 K USD
|
Erck Stanley C
President and CEO |
- 3300
|
179.4794 USD |
|
3 years ago
Oct 04, 2021
|
Sell 90.3 K USD
|
Erck Stanley C
President and CEO |
- 500
|
180.58 USD |
|
3 years ago
Oct 01, 2021
|
Sell 116 K USD
|
Erck Stanley C
President and CEO |
- 703
|
164.7398 USD |
|
3 years ago
Oct 01, 2021
|
Sell 150 K USD
|
Erck Stanley C
President and CEO |
- 904
|
165.683 USD |
|
3 years ago
Oct 01, 2021
|
Sell 183 K USD
|
Erck Stanley C
President and CEO |
- 1100
|
166.6236 USD |
|
3 years ago
Oct 01, 2021
|
Sell 470 K USD
|
Erck Stanley C
President and CEO |
- 2801
|
167.8829 USD |
|
3 years ago
Oct 01, 2021
|
Sell 331 K USD
|
Erck Stanley C
President and CEO |
- 1959
|
169.053 USD |
|
3 years ago
Oct 01, 2021
|
Sell 153 K USD
|
Erck Stanley C
President and CEO |
- 901
|
170.0704 USD |
|
3 years ago
Oct 01, 2021
|
Sell 446 K USD
|
Erck Stanley C
President and CEO |
- 2602
|
171.3352 USD |
|
3 years ago
Oct 01, 2021
|
Sell 706 K USD
|
Erck Stanley C
President and CEO |
- 4103
|
172.0242 USD |
|
3 years ago
Oct 01, 2021
|
Sell 520 K USD
|
Erck Stanley C
President and CEO |
- 3002
|
173.1625 USD |
|
3 years ago
Oct 01, 2021
|
Sell 1.02 M USD
|
Erck Stanley C
President and CEO |
- 5853
|
174.2996 USD |
|
3 years ago
Oct 01, 2021
|
Sell 631 K USD
|
Erck Stanley C
President and CEO |
- 3602
|
175.1465 USD |
|
3 years ago
Oct 01, 2021
|
Sell 458 K USD
|
Erck Stanley C
President and CEO |
- 2601
|
176.2353 USD |
|
3 years ago
Oct 01, 2021
|
Sell 1.1 M USD
|
Erck Stanley C
President and CEO |
- 6227
|
177.3686 USD |
|
3 years ago
Oct 01, 2021
|
Sell 821 K USD
|
Erck Stanley C
President and CEO |
- 4604
|
178.2695 USD |
|
3 years ago
Oct 01, 2021
|
Sell 237 K USD
|
Erck Stanley C
President and CEO |
- 1323
|
179.2895 USD |
|
3 years ago
Oct 01, 2021
|
Sell 458 K USD
|
Erck Stanley C
President and CEO |
- 2541
|
180.4239 USD |
|
3 years ago
Oct 01, 2021
|
Sell 290 K USD
|
Erck Stanley C
President and CEO |
- 1600
|
181.2088 USD |
|
3 years ago
Oct 01, 2021
|
Sell 54.7 K USD
|
Erck Stanley C
President and CEO |
- 300
|
182.4033 USD |
|
3 years ago
Oct 01, 2021
|
Sell 35.3 K USD
|
Erck Stanley C
President and CEO |
- 192
|
183.6104 USD |
|
3 years ago
Oct 01, 2021
|
Sell 1.49 K USD
|
Erck Stanley C
President and CEO |
- 8
|
185.71 USD |
|
3 years ago
Oct 01, 2021
|
Sell 18.8 K USD
|
Erck Stanley C
President and CEO |
- 100
|
187.95 USD |
|
3 years ago
Oct 01, 2021
|
Sell 285 K USD
|
Erck Stanley C
President and CEO |
- 1502
|
189.4701 USD |
|
3 years ago
Oct 01, 2021
|
Sell 90 K USD
|
Erck Stanley C
President and CEO |
- 472
|
190.632 USD |
|
3 years ago
Oct 01, 2021
|
Sell 66.2 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
165.395 USD |
|
3 years ago
Oct 01, 2021
|
Sell 16.6 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 100
|
166.19 USD |
|
3 years ago
Oct 01, 2021
|
Sell 50.4 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 300
|
168.0333 USD |
|
3 years ago
Oct 01, 2021
|
Sell 33.8 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 200
|
169.17 USD |
|
3 years ago
Oct 01, 2021
|
Sell 103 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 600
|
171.6 USD |
|
3 years ago
Oct 01, 2021
|
Sell 34.5 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 200
|
172.46 USD |
|
3 years ago
Oct 01, 2021
|
Sell 69.5 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
173.825 USD |
|
3 years ago
Oct 01, 2021
|
Sell 69.9 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 400
|
174.7375 USD |
|
3 years ago
Oct 01, 2021
|
Sell 88 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 500
|
175.906 USD |
|
3 years ago
Oct 01, 2021
|
Sell 88.5 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 500
|
177.018 USD |
|
3 years ago
Oct 01, 2021
|
Sell 107 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 600
|
177.9967 USD |
|
3 years ago
Oct 01, 2021
|
Sell 63.1 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 352
|
179.2695 USD |
|
3 years ago
Oct 01, 2021
|
Sell 18.1 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 100
|
181.36 USD |
|
3 years ago
Oct 01, 2021
|
Sell 56.9 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 300
|
189.6833 USD |
|
3 years ago
Oct 01, 2021
|
Sell 9.15 K USD
|
Herrmann John A III
EVP, Chief Legal Officer |
- 48
|
190.63 USD |
|
3 years ago
Sep 30, 2021
|
Sell 10.3 K USD
|
Glenn Gregory M
President, R&D |
- 51
|
202.8373 USD |
|
3 years ago
Sep 30, 2021
|
Sell 11.2 K USD
|
Glenn Gregory M
President, R&D |
- 55
|
203.9373 USD |
|
3 years ago
Sep 30, 2021
|
Sell 3.28 K USD
|
Glenn Gregory M
President, R&D |
- 16
|
205.01 USD |
|
3 years ago
Sep 30, 2021
|
Sell 58 K USD
|
Glenn Gregory M
President, R&D |
- 280
|
207.0077 USD |
|
3 years ago
Sep 30, 2021
|
Sell 24.3 K USD
|
Glenn Gregory M
President, R&D |
- 117
|
207.9946 USD |
|
3 years ago
Sep 30, 2021
|
Sell 24.7 K USD
|
Glenn Gregory M
President, R&D |
- 118
|
209.2718 USD |
|
3 years ago
Sep 30, 2021
|
Sell 8.41 K USD
|
Glenn Gregory M
President, R&D |
- 40
|
210.1605 USD |
|
3 years ago
Sep 30, 2021
|
Sell 3.38 K USD
|
Glenn Gregory M
President, R&D |
- 16
|
211.39 USD |
|
3 years ago
Sep 27, 2021
|
Sell 13 K USD
|
Glenn Gregory M
President, R&D |
- 57
|
228.12 USD |
|
3 years ago
Sep 27, 2021
|
Sell 51.7 K USD
|
Glenn Gregory M
President, R&D |
- 225
|
229.9924 USD |
|
3 years ago
Sep 27, 2021
|
Sell 62.9 K USD
|
Glenn Gregory M
President, R&D |
- 272
|
231.0668 USD |
|
3 years ago
Sep 27, 2021
|
Sell 73.8 K USD
|
Glenn Gregory M
President, R&D |
- 318
|
231.9969 USD |
|
3 years ago
Sep 27, 2021
|
Sell 61.1 K USD
|
Glenn Gregory M
President, R&D |
- 262
|
233.2368 USD |
|
3 years ago
Sep 27, 2021
|
Sell 50.7 K USD
|
Glenn Gregory M
President, R&D |
- 217
|
233.8694 USD |
|
3 years ago
Sep 27, 2021
|
Sell 47.7 K USD
|
Glenn Gregory M
President, R&D |
- 203
|
235.1024 USD |
|
3 years ago
Sep 27, 2021
|
Sell 23.2 K USD
|
Glenn Gregory M
President, R&D |
- 98
|
236.295 USD |
|
3 years ago
Sep 27, 2021
|
Sell 13.5 K USD
|
Glenn Gregory M
President, R&D |
- 57
|
237.29 USD |
|
3 years ago
Sep 27, 2021
|
Sell 29.6 K USD
|
Glenn Gregory M
President, R&D |
- 124
|
239.041 USD |
|
3 years ago
Sep 27, 2021
|
Sell 23.8 K USD
|
Glenn Gregory M
President, R&D |
- 99
|
240.3657 USD |
|
3 years ago
Sep 27, 2021
|
Sell 13.7 K USD
|
Glenn Gregory M
President, R&D |
- 56
|
243.9805 USD |
|
3 years ago
Sep 27, 2021
|
Sell 23.6 K USD
|
Glenn Gregory M
President, R&D |
- 95
|
248.134 USD |
|
3 years ago
Sep 28, 2021
|
Sell 171 K USD
|
Trizzino John
EVP, CCO and CBO |
- 839
|
203.2628 USD |
|
3 years ago
Sep 28, 2021
|
Sell 233 K USD
|
Trizzino John
EVP, CCO and CBO |
- 1141
|
204.123 USD |
|
3 years ago
Sep 28, 2021
|
Sell 298 K USD
|
Trizzino John
EVP, CCO and CBO |
- 1452
|
205.2541 USD |
|
3 years ago
Sep 28, 2021
|
Sell 204 K USD
|
Trizzino John
EVP, CCO and CBO |
- 990
|
206.3028 USD |
|
3 years ago
Sep 28, 2021
|
Sell 79.2 K USD
|
Trizzino John
EVP, CCO and CBO |
- 382
|
207.319 USD |
|
3 years ago
Sep 28, 2021
|
Sell 65 K USD
|
Trizzino John
EVP, CCO and CBO |
- 312
|
208.4567 USD |
|
3 years ago
Sep 28, 2021
|
Sell 23.5 K USD
|
Trizzino John
EVP, CCO and CBO |
- 112
|
209.57 USD |
|
3 years ago
Sep 28, 2021
|
Sell 21.1 K USD
|
Trizzino John
EVP, CCO and CBO |
- 100
|
211.45 USD |
|
3 years ago
Sep 28, 2021
|
Sell 6.39 K USD
|
Trizzino John
EVP, CCO and CBO |
- 30
|
213.11 USD |
|
3 years ago
Sep 28, 2021
|
Sell 68.3 K USD
|
Trizzino John
EVP, CCO and CBO |
- 318
|
214.6475 USD |
|
3 years ago
Sep 28, 2021
|
Sell 53.4 K USD
|
Trizzino John
EVP, CCO and CBO |
- 247
|
216.2094 USD |
|
3 years ago
Sep 28, 2021
|
Sell 49.3 K USD
|
Trizzino John
EVP, CCO and CBO |
- 226
|
218.1284 USD |
|
3 years ago
Sep 28, 2021
|
Sell 92.3 K USD
|
Trizzino John
EVP, CCO and CBO |
- 421
|
219.2639 USD |
|
3 years ago
Sep 28, 2021
|
Sell 10.8 K USD
|
Trizzino John
EVP, CCO and CBO |
- 49
|
220.2218 USD |
|
3 years ago
Sep 28, 2021
|
Sell 56.8 K USD
|
Trizzino John
EVP, CCO and CBO |
- 255
|
222.8629 USD |
|
3 years ago
Sep 28, 2021
|
Sell 33.2 K USD
|
Trizzino John
EVP, CCO and CBO |
- 148
|
224.2398 USD |
|
3 years ago
Sep 28, 2021
|
Sell 73.7 K USD
|
Trizzino John
EVP, CCO and CBO |
- 323
|
228.2517 USD |
|
3 years ago
Sep 28, 2021
|
Sell 35.9 K USD
|
Trizzino John
EVP, CCO and CBO |
- 156
|
229.9977 USD |
|
3 years ago
Sep 27, 2021
|
Sell 71.8 K USD
|
Trizzino John
EVP, CCO and CBO |
- 314
|
228.6862 USD |
|
3 years ago
Sep 27, 2021
|
Sell 145 K USD
|
Trizzino John
EVP, CCO and CBO |
- 628
|
230.1874 USD |
|
3 years ago
Sep 27, 2021
|
Sell 316 K USD
|
Trizzino John
EVP, CCO and CBO |
- 1365
|
231.1575 USD |
|
3 years ago
Sep 27, 2021
|
Sell 214 K USD
|
Trizzino John
EVP, CCO and CBO |
- 924
|
231.9506 USD |
|
3 years ago
Sep 27, 2021
|
Sell 296 K USD
|
Trizzino John
EVP, CCO and CBO |
- 1270
|
233.2479 USD |
|
3 years ago
Sep 27, 2021
|
Sell 199 K USD
|
Trizzino John
EVP, CCO and CBO |
- 849
|
234.3748 USD |
|
3 years ago
Sep 27, 2021
|
Sell 87 K USD
|
Trizzino John
EVP, CCO and CBO |
- 369
|
235.7704 USD |
|
3 years ago
Sep 27, 2021
|
Sell 63.2 K USD
|
Trizzino John
EVP, CCO and CBO |
- 267
|
236.7451 USD |
7. News
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Human Services (HHS).
fastcompany.com
- 1 day ago
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.
investopedia.com
- 1 day ago
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md. , Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non- qualified stock option and restricted stock units to Ruxandra Draghia-Akli, MD, PhD, its newly appointed Executive Vice President and Head of Research & Development, as a material inducement for her entry into employment with Novavax, effective as of November 11, 2024 (the "grant date").
prnewswire.com
- 1 day ago
Novavax, Inc. (NVAX) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
accesswire.com
- 2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accesswire.com
- 2 days ago
NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
accesswire.com
- 2 days ago
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.
zacks.com
- 3 days ago
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md. , Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.
prnewswire.com
- 3 days ago
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines.
seekingalpha.com
- 3 days ago
NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
accesswire.com
- 4 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accesswire.com
- 4 days ago
Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer John Trizzino - President and Chief Operating Officer Robert Walker - Senior Vice President and Chief Medical Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Eric Joseph - JPMorgan Vernon Bernardino - H.C.
seekingalpha.com
- 4 days ago
8. Profile Summary
Novavax, Inc. NVAX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.17 B
Dividend Yield
0.00%
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Contact
21 Firstfield Road, Gaithersburg, MD, 20878
https://www.novavax.com
IPO Date
Dec. 5, 1995
Employees
1543
Officers
Ms. Erika S. Trahan
Associate Director of Investor & Public Relations
Mr. Ian J. Watkins
Executive Vice President & Chief Human Resources Officer
Mr. Troy Morgan Esq., J.D.
Senior Vice President, Deputy General Counsel & Chief Compliance Officer
Mr. Richard P. Crowley
Executive Vice President & Chief Operating Officer
Ms. Silvia Taylor M.B.A.
Executive Vice President and Chief Corporate Affairs & Advocacy Officer
Mr. John Charles Jacobs M.B.A.
President, Chief Executive Officer & Director
Mr. James Patrick Kelly C.F.A.
Executive Vice President, Chief Financial Officer & Treasurer
Dr. Robert Walker M.D.
Senior Vice President, Chief Medical Officer and Interim Head of R&D
Mr. John Joseph Trizzino B.S., M.B.A.
President & Chief Operating Officer
Mr. Mark Casey
Executive Vice President, Chief Legal Officer & Corporate Secretary